RNA Sequencing Analysis for the Identification of a < b > < i > PCM1/PDGFRB < /i > < /b > Fusion Gene Responsive to Imatinib

This study shows that the combination of different strategies is pivotal to fine-tune the diagnosis and the clinical management of the patient. After 1 year of treatment with imatinib, the patient achieves hematological and molecular remission. We present an attractive strategy to identify novel and/or cryptic fusions, which will be relevant for clinicians dealing with the diagnosis of the patients with myelodysplastic syndrome/myeloproliferative diseases with atypical manifestations.Acta Haematol
Source: Acta Haematologica - Category: Hematology Source Type: research